Hirschfeld D S, Ueda C T, Rowland M, Scheinman M M
Br Heart J. 1977 Mar;39(3):309-16. doi: 10.1136/hrt.39.3.309.
Quinidine gluconate (total dose 4-4 to 9-1 mg/kg) was infused intravenously over 22 minutes in 20 patients with either frequent premature ventricular contractions or supraventricular arrhythmias, 16 of whom had bundle-branch block. Therapeutic plasma quinidine levels (3 to 7 mg/l) were achieved in 15. Heart rate, atrioventricular nodal, and infranodal conduction times did not change significantly. The QRS duration increased significantly from 128+/-30 to 134+/-29 ms at peak plasma quinidine levels (P less than 0.01). Mild hypotension occurred during infusion in most patients. Two patients had a severe but transient toxic response characterised by hypotension, nausea, vomiting, and diaphoresis. Atrioventricular dissociation with escape His bundle or fascicular rhythm occurred in 1 patient with sinus bradycardia. Bundle-branch block does not contraindicate administration of quinidine. Quinidine gluconate administered intravenously (0-3 to 0-4 mg/kg per min) is frequently associated with hypotenstion and should be used only in an intensive care setting and with careful monitoring of blood pressure.
对20例频发室性早搏或室上性心律失常患者静脉输注葡萄糖酸奎尼丁(总剂量4.4至9.1毫克/千克),输注时间为22分钟,其中16例患者存在束支传导阻滞。15例患者达到了治疗性血浆奎尼丁水平(3至7毫克/升)。心率、房室结及结下传导时间无明显变化。在血浆奎尼丁水平峰值时,QRS时限从128±30毫秒显著增加至134±29毫秒(P<0.01)。大多数患者在输注过程中出现轻度低血压。2例患者出现严重但短暂的毒性反应,表现为低血压、恶心、呕吐和出汗。1例窦性心动过缓患者出现房室分离并伴有希氏束或分支逸搏心律。束支传导阻滞并非使用奎尼丁的禁忌证。静脉输注葡萄糖酸奎尼丁(每分钟0.3至0.4毫克/千克)常伴有低血压,应仅在重症监护环境下使用,并需密切监测血压。